Todos Medical Announces Commercialization of Lesio
Post# of 1418
(Total Views: 288)
Posted On: 08/22/2022 9:09:40 AM
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Provista begins validation preparations for blood-based IgM/IgG MonkeyPox
LDTCompany to release its Q2/2022 10Q quarterly report at 4:05 pm ET this afternoon
Company to host business update conference call on Tuesday, August 23rd at 8:30 am ET
New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has completed CLIA validation and has commercially-launched PCR-based MonkeyPox testing in the United States.
The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 1.2 viral copies per reaction (0.12 copies/ul), with identical sensitivity (1.2 viral copies per reaction) achieved for its saliva-based test that has also completed CLIA validation protocols. Provista has also completed implementation of upgraded safety protocols to be in compliance recommended CDC protocols for MonkeyPox which are in line with biosafety 3 level (BSL3) laboratory protocols. Provista will collect saliva samples matched with lesion swabs from confirmed MonkeyPox cases before launching a standalone LDT targeted at identifying MonkeyPox in the pre-symptomatic stage. In situations of known exposure to confirmed or suspected MonkeyPox cases for which there are no symptoms, Provista intends to make saliva-based MonkeyPox PCR testing available that may make them eligible for the FDA approved MonkeyPox vaccine Jynneos or Tecovirimat (TPoxx) antiviral therapy under an early access investigational new drug application (EA-IND) through the CDC, in partnership with the US Food & Drug Administration (FDA). Other uses of PCR MonkeyPox testing include wastewater surveillance, as well as wild animal surveillance to understand whether animal populations begin to carry viral reservoir that could ultimately spillover back into new human populations. The Company is also preparing validation plans for an IgM/IgG blood-based MonkeyPox LDT to confirm recent infection as part of a planned MonkeyPox Panel.
“We are positioning Provista to become a leader in MonkeyPox testing given that MonkeyPox has been recently labeled a public health emergency by the US Government, and as such there is an urgent need to ramp up testing availability in order to facilitate the containment of outbreaks,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Anyone can be infected with MonkeyPox through skin-to-skin contact, sexual intercourse, skin contact with virus-laden surfaces such as bedsheets, as well as through prolonged exposure to MonkeyPox-laden aerosols and/or respiratory droplets. MonkeyPox has an incubation period of up to three weeks. During the current MonkeyPox outbreak in the US, the virus is primarily being diagnosed in the male gay community. However recent spillover has been documented in women, children and infants which raises the possibility of a wider outbreak that could make its way into broader circulation in the general population. As such, it is imperative to support the male gay community and the broader community’s mitigation efforts by making MonkeyPox testing more broadly available in ways that will allow patients to be diagnosed sooner, hopefully during the pre-symptomatic stage where intervention is likely to be most effective.”
Mr. Commissiong continued, “Currently the US has capacity to test approximately 80,000 samples per week. If we are to contain MonkeyPox and prevent it from becoming endemic to the United States, we must dramatically ramp up testing of not only lesion-based samples that require someone’s infection to become symptomatic, but also saliva-based samples that likely provides the best opportunity to diagnose patients much earlier in disease pathogenesis. Provista currently has PCR automation capacity to run 25,000 PCR tests per day, or 175,000 PCR tests per week, with ongoing efforts to increase this capacity to 50,000 PCR tests per day, or 350,000 PCR tests per week. Additionally, our supplier of materials that allowed us to quickly complete the development of our LDT has sufficient capacity to manufacture and deliver well over 1,000,000 PCR assays per week for the US market, which we intend to also deploy as needed through our Corona Diagnostics distribution arm to clients of ours and assist them with assay validation in the event there is a need for testing beyond Provista’s capabilities. The availability of this increased testing capacity and materials supply to aid in the US MonkeyPox public health emergency mitigation efforts, coupled with saliva testing for mildly symptomatic and asymptomatic individuals, will provide the opportunity to dramatically accelerate contact tracing efforts by serially testing of exposed individuals in order to give greater certainty to the individual that they are not infected or contagious, and provide the needed better opportunities to break the chains of infection.”
Concurrent with this announcement, the Company will release its 10Q quarterly financial statements for the second quarter of 2022 after market close at 4:05 pm Eastern time and hold a business update conference call on Tuesday, August 23rd, 2022 at 8:30 am Eastern time.
https://investor.todosmedical.com/news-events...lesion-and
Provista begins validation preparations for blood-based IgM/IgG MonkeyPox
LDTCompany to release its Q2/2022 10Q quarterly report at 4:05 pm ET this afternoon
Company to host business update conference call on Tuesday, August 23rd at 8:30 am ET
New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has completed CLIA validation and has commercially-launched PCR-based MonkeyPox testing in the United States.
The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 1.2 viral copies per reaction (0.12 copies/ul), with identical sensitivity (1.2 viral copies per reaction) achieved for its saliva-based test that has also completed CLIA validation protocols. Provista has also completed implementation of upgraded safety protocols to be in compliance recommended CDC protocols for MonkeyPox which are in line with biosafety 3 level (BSL3) laboratory protocols. Provista will collect saliva samples matched with lesion swabs from confirmed MonkeyPox cases before launching a standalone LDT targeted at identifying MonkeyPox in the pre-symptomatic stage. In situations of known exposure to confirmed or suspected MonkeyPox cases for which there are no symptoms, Provista intends to make saliva-based MonkeyPox PCR testing available that may make them eligible for the FDA approved MonkeyPox vaccine Jynneos or Tecovirimat (TPoxx) antiviral therapy under an early access investigational new drug application (EA-IND) through the CDC, in partnership with the US Food & Drug Administration (FDA). Other uses of PCR MonkeyPox testing include wastewater surveillance, as well as wild animal surveillance to understand whether animal populations begin to carry viral reservoir that could ultimately spillover back into new human populations. The Company is also preparing validation plans for an IgM/IgG blood-based MonkeyPox LDT to confirm recent infection as part of a planned MonkeyPox Panel.
“We are positioning Provista to become a leader in MonkeyPox testing given that MonkeyPox has been recently labeled a public health emergency by the US Government, and as such there is an urgent need to ramp up testing availability in order to facilitate the containment of outbreaks,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Anyone can be infected with MonkeyPox through skin-to-skin contact, sexual intercourse, skin contact with virus-laden surfaces such as bedsheets, as well as through prolonged exposure to MonkeyPox-laden aerosols and/or respiratory droplets. MonkeyPox has an incubation period of up to three weeks. During the current MonkeyPox outbreak in the US, the virus is primarily being diagnosed in the male gay community. However recent spillover has been documented in women, children and infants which raises the possibility of a wider outbreak that could make its way into broader circulation in the general population. As such, it is imperative to support the male gay community and the broader community’s mitigation efforts by making MonkeyPox testing more broadly available in ways that will allow patients to be diagnosed sooner, hopefully during the pre-symptomatic stage where intervention is likely to be most effective.”
Mr. Commissiong continued, “Currently the US has capacity to test approximately 80,000 samples per week. If we are to contain MonkeyPox and prevent it from becoming endemic to the United States, we must dramatically ramp up testing of not only lesion-based samples that require someone’s infection to become symptomatic, but also saliva-based samples that likely provides the best opportunity to diagnose patients much earlier in disease pathogenesis. Provista currently has PCR automation capacity to run 25,000 PCR tests per day, or 175,000 PCR tests per week, with ongoing efforts to increase this capacity to 50,000 PCR tests per day, or 350,000 PCR tests per week. Additionally, our supplier of materials that allowed us to quickly complete the development of our LDT has sufficient capacity to manufacture and deliver well over 1,000,000 PCR assays per week for the US market, which we intend to also deploy as needed through our Corona Diagnostics distribution arm to clients of ours and assist them with assay validation in the event there is a need for testing beyond Provista’s capabilities. The availability of this increased testing capacity and materials supply to aid in the US MonkeyPox public health emergency mitigation efforts, coupled with saliva testing for mildly symptomatic and asymptomatic individuals, will provide the opportunity to dramatically accelerate contact tracing efforts by serially testing of exposed individuals in order to give greater certainty to the individual that they are not infected or contagious, and provide the needed better opportunities to break the chains of infection.”
Concurrent with this announcement, the Company will release its 10Q quarterly financial statements for the second quarter of 2022 after market close at 4:05 pm Eastern time and hold a business update conference call on Tuesday, August 23rd, 2022 at 8:30 am Eastern time.
https://investor.todosmedical.com/news-events...lesion-and
(2)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼